Abaloparatide (Tymlos) is an FDA-approved bone anabolic agent representing the second generation of PTH-pathway osteoporosis therapeutics. By targeting the PTH1 receptor through PTHrP-like binding rather than PTH-like binding (as teriparatide does), it achieves bone formation with potentially less hypercalcemia risk and a more favorable bone formation/resorption ratio.
Dosage Information (Research Use)
80mcg SC once daily in the periumbilical region. Maximum treatment duration: 2 years. Prescription medication.
Reconstitution & Handling
Pre-filled pen — no reconstitution.
Half-Life & Pharmacokinetics
~1 hour
Reported Observations in Literature
Injection site reactions (redness, edema) — most common (44%). Hypercalcemia (3.4%), dizziness (10%), nausea (8%). Orthostatic hypotension may occur with first doses. Black box warning: osteosarcoma risk (rodent data — clinical relevance uncertain).
Key Research References
- Miller PD et al. “Effect of abaloparatide vs placebo on new vertebral fractures (ACTIVE).” JAMA. 2016;316:722-33